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“Mucositis” is the clinical term used to describe ulceration and damage of the mucous membranes of the entire gastrointestinal
tract (GIT) following cytotoxic cancer chemotherapy and radiation therapy common symptoms include abdominal pain, bloating,
diarrhoea, vomiting, and constipation resulting in both a significant clinical and financial burden. Chemotherapeutic drugs cause
upregulation of stress response genes including NFκB, that in turn upregulate the production of proinflammatory cytokines such
as interleukin-1β (IL-1β), Interleukin-6 (IL-6), and tumour necrosis factor-α (TNF-α). These proinflammatory cytokines are
responsible for initiating inflammation in response to tissue injury. Anti-inflammatory cytokines and specific cytokine inhibitors
are also released to limit the sustained or excessive inflammatory reactions. In the past decade, intensive research has determined
the role of proinflammatory cytokines in development of mucositis. However, a large gap remains in the knowledge of the role of
anti-inflammatory cytokines in the setting of chemotherapy-induced mucositis. This critical paper will highlight current literature
available relating to what is known regarding the development of mucositis, including the molecular mechanisms involved in
inducing inflammation particularly with respect to the role of proinflammatory cytokines, as well as provide a detailed discussion
of why it is essential to consider extensive research in the role of anti-inflammatory cytokines in chemotherapy-induced mucositis
so that eﬀective targeted treatment strategies can be developed.
1. Introduction
Cancer patients receiving chemotherapy and/or radiation
therapy often develop mucositis as a direct result of their
treatment. The term “mucositis” specifically refers to the
damage of mucous membranes throughout the entire gas-
trointestinal tract (GIT) following chemotherapy and radio-
therapy [1–3]. It is a major oncological problem reported
in approximately 40% of patients undergoing standard dose
chemotherapy and in almost all patients receiving high-
dose chemotherapy and stem cell transplantation [4–7]. The
prevalence of mucositis also varies depending on the type of
cancer and therefore the combination of cytotoxic drugs [8,
9]. For example, patients treated with 5-fluorouracil (5-FU),
often experience more severe mucositis [9]. Patients with
mucositis exhibit severe clinical symptoms including pain
due to ulceration of the GIT, nausea, vomiting, heartburn,
diarrhoea, constipation, and therefore severe weight loss
[1, 4, 7]. Furthermore, ulceration of the GIT is commonly
associated with a high risk of systemic infection which
poses a threat to patient health [10]. Mucositis can result
in unplanned treatment interruptions including dosage
reduction or premature cessation of cancer treatment [1,
3, 7]. Patients may require prolonged hospitalization and
administration of antibiotic, antiviral therapy, or antifungal
drugs depending on the severity of the condition [9, 10].
Currently, management of mucositis is largely supported
with treatment limited to pain relief, maintenance of good
oral hygiene, and the use of loperamide (a nonanalgesic
opioid) to treat diarrhoea [11]. Hence, mucositis is a major
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clinical and economic burden that severely impacts patients’
quality of life and increases their risk of morbidity and
mortality [12]. Within the previous decade, intense research
has clarified the complex sequence of molecular events
underlying the pathobiology of mucositis and the develop-
ment of novel treatments and strategies in the management
of mucositis.
2. Pathobiology of Mucositis
The pathobiology of mucositis is complex and involves the
interplay of multiple intricate pathways including molec-
ular and cellular events that occur in all layers of the
gastrointestinal mucosa [13]. Historically, it was assumed
that mucositis development was simply an epithelial phe-
nomenon and occurred due to the direct toxic eﬀect of
cytotoxic chemotherapeutic agents on the basal cells of the
gastrointestinal tract epithelium [9, 14, 15]. However, recent
investigations have clearly identified that mucositis devel-
opment is complicated with the involvement of molecular
pathways between all mucosal compartments [8, 9, 15–17].
Initially, mucositis development was proposed in a four-stage
model by Sonis in 1998 [18]. However subsequent studies
have further extending this model into a five stage model
comprising of the (1) initiation, (2) upregulation and message
generation, (3) signalling and amplification, (4) ulceration and
inflammation, and (5) healing phase [9, 14, 19, 20].
Briefly, the initiation phase occurs immediately following
exposure to cytotoxic therapy resulting in direct damage to
cellular DNA leading to immediate cell injury or death in
the basal epithelia and submucosal cells [9, 13]. Furthermore,
extensive tissue injury can result in the generation of reactive
oxygen species (ROS). ROS are known to cause damage
to cells and tissues, stimulate macrophages, and trigger a
cascade of inflammatory pathways including the SP1-related
retinoblastoma control protein, p53, and the nuclear factor
kappa-B (NF-κB) inflammatory pathway which is described
in detail later in this paper [14, 21, 22].
The upregulation and message generation phase involves
the activation of a number of signalling pathways and tran-
scription factors, most importantly NFκB [13, 23]. NFκB
in turn mediates gene expression and synthesis of var-
ious inflammatory molecules including proinflammatory
cytokines such as tumour-necrosis factor (TNF), interleukin-
6 (IL-6), interleukin-1β (IL-1β), adhesion molecules, and
cyclooxygenase-2 (COX-2) from adjacent connective tissue
[21, 22, 24]. The initiation of this inflammatory cascade has
been confirmed in the clinical setting where studies have
demonstrated the presence of these inflammatory factors in
peripheral blood samples of chemotherapy patients [24, 25].
Signal amplification is the third phase of mucositis devel-
opment where the inflammation signal is further amplified
as a consequence of proinflammatory cytokines such as
TNF acting in a positive feedback loop to reinforce NFκB
activation [13, 18, 21]. The net eﬀect of this amplified
inflammatory positive feedback loop is enhanced production
of proinflammatory cytokines (TNF, IL-6, and IL-1β) and
further tissue damage as a result of increased apoptosis.
Mucositis is clinically evident during the fourth ulcer-
ative phase where the gastrointestinal epithelium integrity
is destroyed. The GIT epithelium is characterised by the
formation of pseudomembranes and ulcers [13, 15, 18, 21].
Bacterial colonisation at the site of ulceration further induces
inflammation and activates the infiltration of macrophages
and other inflammatory cells to the site of tissue injury [26].
The final healing phase occurs within approximately
two weeks following cessation of treatment [21] and is
a spontaneous self-resolving process where the intestinal
epithelium is renewed. Although it remains the least under-
stood stage of mucositis, it is thought that COX-2 may
play an important “rebuilding” role in the healing phase by
initiating angiogenesis which is predominantly seen in this
phase [21, 27].
3. Inflammatory Signalling Pathways
in Mucositis
3.1. The Role of Cytokines in Tissue Inflammation. Cytokines
are pleiotropic endogenous inflammatory and immunomod-
ulating mediators that exhibit both negative and positive
regulatory eﬀects on various target cells [28–30]. These
cell-derived polypeptides closely orchestrate both acute
and chronic inflammatory processes by acting locally or
systemically on the site of tissue infection via autocrine and
paracrine pathways [30]. Briefly, inflammation at the site of
infected tissue arises from the activation of various resident
inflammatory cells such as fibroblasts, endothelial cells,
tissue macrophages, and mast cells as well as the recruitment
of monocytes, lymphocytes, and neutrophils [30]. This
aggregation of inflammatory cells at the site of inflammation
is initiated by a number of soluble mediators such as
cytokines, inflammatory lipid metabolites such as platelet
activating factor (PAF), and derivatives of arachidonic acid
such as prostaglandins [30]. Such inflammatory eﬀects can
give rise to swelling due to fluid accumulation, increased
blood flow and vascular permeability resulting in redness,
and pain [30]. As inflammation closely correlates with the
production of cytokines, inflammatory events that occur
during mucositis development have also been thought to be
associated with the generation of cytokine signalling cascade
[29].
3.2. Nuclear Factor κB (NFκB): A “Gate-Keeper” Sec-
ondary Messenger. Evidence from previous literature clearly
describes the role of nuclear factor κB (NFκB) transcription
factor in the development of mucositis [8, 9, 31, 32]. NFκB is
a ubiquitous transcription factor that collectively comprises
of the following five members: NF-κB1 (p50/p105), NF-
κB2 (p52/p100), p65 (Rel A), Rel 3, and cRel [9, 33]. It
typically resides as an inactive heterodimer of p65/RelA and
p50 or p52 subunits bound to the members of IκB (Inhibitor
kappa B) proteins in the cell cytoplasm [32, 34]. Upon
activation by an extensive range of agents such as bacteria
and bacterial cell wall products, viruses, cytokines, free
radicals scavengers from oxidative stress, ionizing radiation,
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and even the use of antineoplastic agents (cisplatin, doxoru-
bicin, taxol, paclitaxel, and etoposide), NFκB acts to induce
gene expression of many cytokines involved predominantly
in mucosal inflammation, and angiogenesis, chemokines,
immunoreceptors, cell adhesion molecules, proapoptotic
and antiapoptotic as well as stress response genes [9, 31–
33]. On amolecular level, NFκB stimulation signals cause the
phosphorylation of NFκB inhibitory protein IκB, located in
cell cytoplasm [35]. This results in the dissociation of bound
NFκB from IκB which is subsequently translocated to the cell
nucleus where it upregulates the expression of approximately
200 genes [8]. IκB is further degraded by proteases [14].
In the past decade, much attention has been given to
the diverse roles NFκB plays in generating tissue response by
targeting a wide range of genes [8, 34]. Its role in potentiating
inflammatory and immune responses by inducing various
proinflammatory cytokines production such as TNF, IL-6
and IL-1β involved in the development of mucositis has
been widely recognised with the use of animal models and
in the clinical setting [5, 34]. NFκB is considered a key
“driver” of chemotherapy-induced mucositis as its activation
correlates with the production of TNF, IL-6 and IL-1β the
hallmarks of mucositis inflammation [8, 36]. In particular,
cytotoxic drug administration results in the upregulation of
NFκB and subsequently proinflammatory cytokine (TNF, IL-
6, and IL-1β) levels [8, 37, 38]. In further support of this,
Logan et al. (2008) reported a significant rise in serumNFκB,
TNF, IL-6, and IL-1β levels following administration of three
diﬀerent chemotherapeutic drugs known to cause mucositis
[37]. Irinotecan, a commonly used cytotoxic agent, has also
been shown to significantly elevate NFκB production in the
oral mucosa, jejunum, and colon [8, 34]. This elevation
ultimately culminates in villus blunting, epithelial atrophy,
and increased inflammatory cell infiltration in all tissues [8].
Further research clearly indicates that NFκB activation is
stimulated by chemotherapeutic agents thus leading to the
production of proinflammatory cytokines, TNF, IL-6, and
IL-1β, resulting in mucosal damage [8, 37, 38].
In support of the animal studies, clinical evidence is also
available. Research from our group has further demonstrated
a significant rise in tissue NFκB levels in the oral buccal
mucosa of cancer patients undergoing chemotherapy [34].
Yeoh et al. (2005) published data correlating histopatholog-
ical changes with increased NFκB and COX-2 expression
in the colonic mucosa of patients treated with ionizing
radiation [5]. In addition, ionizing radiation-induced NFκB
activation has been reported in other studies where radiation
is known to cause the generation of oxygen free radicals,
damage to cellular components, and breakage of the DNA
double strands [39–41]. These inflammatory markers are
essential in the pathogenesis of mucositis development and
therefore in assessing the severity of tissue damage.
4. Proinflammatory Cytokines
and Inflammation
As described earlier, the activation of NFκB results in the
production of proinflammatory mediators such as TNF, IL-
6, and IL-1β [8, 9, 18, 21, 28]. This subclass of cytokines
is referred to as “proinflammatory cytokines” due to their
ability to promote inflammation in response to tissue
injury and infection [42]. Another subclass of cytokines
is the “anti-inflammatory cytokines” which are involved in
suppressing the activity of proinflammatory cytokines hence
downregulating the inflammatory response [43]. Overex-
pression of anti-inflammatory cytokines is known to lead
to depression of the immune system thus rendering the
host at risk of systemic infection [43, 44]. Previous studies
have directly implicated the presence of TNF, IL-6, and
IL-1β proinflammatory cytokines in the pathogenesis of a
number of inflammatory diseases, such as inflammatory
bowel disease (IBD) [45], rheumatoid arthritis [46], sepsis
[47], and most importantly, in mucositis [8, 13, 21, 34].
The role of proinflammatory cytokines has been discussed in
detail in other critical reviews and is outside the scope of this
paper. For further details please refer to Logan Review [8].




Under normal physiological conditions, the human immune
system comprises of multiple redundant pathways and
immunoregulatory control elements that act in concert
to coordinate the immune response initiated upon an
external signal [43]. Of these multifaceted components of the
immune system, the anti-inflammatory cytokine component
has been subject to in-depth research for years. Studying the
regulation of inflammation by these cytokine inhibitors is
complicated as a number of related external factors must
be considered for appropriate understanding and analysis
of net eﬀect of these cytokines. It has been postulated that
factors such as timing of cytokine release, local environment
in which it acts, presence of competing or synergistic
elements, nature of target cells, availability and density of
specific cytokine receptors, and tissue-specific response to
each cytokine determine their net eﬀect [43]. In addition,
the discovery of various proinflammatory cytokines has
further added to the complexity of the intricate pathways
that occur during an immune response. Collective findings
from a wide range of cytokine investigations indicate that
the net eﬀect of the inflammatory response is determined
by a delicate balance between pro- and anti-inflammatory
cytokines [43] as shown in Figure 1. Perturbations in this
equilibrium can drive the host defence immune response
either towards chronic inflammation or towards healing
[43]. To date, various anti-inflammatory cytokines have been
acknowledged in literature and these include IL-1ra, IL-4, IL-
6, IL-10, IL-11, IL-13, TGF-β, and various soluble cytokine
receptors [43]. This literature paper will address four of these
anti-inflammatory cytokines in detail: IL-4, IL-10, IL-11, and
IL-1ra.
5.1. Interleukin-4 (IL-4). IL-4 is a 20-kDa polypeptide
secreted by mature Th-2 type helper T cells, mast cells, and
basophils [48, 49]. IL-4 has marked inhibitory eﬀects on
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Figure 1: Possible negative feedback mechanism between pro- and anti-inflammatory cytokines IL-10, IL-4, and IL-11 following intestinal
damage and inflammation.
the expression and release of proinflammatory cytokines
[43]. Molecular and structural analysis of the IL-4 receptor
has identified the 140-kDa IL-4Rα chain where high-aﬃnity
binding with IL-4 occurs and further dimerization of
this complex with the γ-chain mediates intracellular cell
signalling [50, 51]. These cell surface IL-4 receptor complexes
have been discovered in an extensive range of tissues includ-
ing hematopoietic, endothelial, epithelial, muscle, fibroblast,
hepatocytes, and brain tissues thus accounting for their
broad range of activity [50].
IL-4 suppresses IL-1β synthesis, a major proinflam-
matory cytokine involved in inducing inflammation [52].
Furthermore, IL-4 enhances the expression of IL-1 receptor
antagonist (IL-1ra), an antagonist that blocks the binding of
proinflammatory cytokines, IL-1α and IL-1β, to their specific
receptors [52, 53]. Bymediating its action through the widely
expressed IL-4 receptor α (IL-4Rα), IL-4 plays an important
role in tissue adhesion and inflammation as well as poten-
tiates immunological eﬀects against gram-negative bacterial
infections [54, 55]. This highlights the diverse complex
biological eﬀects of IL-4 in mediating immunity through
a unique array of cellular responses. Although evidence
suggests that IL-4 has potential anti-inflammatory eﬀects, its
role during mucositis remains undefined. To date, there is
no evidence to suggest whether IL-4 is produced at tissue
levels in mucositis and if it is upregulated during diﬀerent
stages of mucositis. Thus it is obligatory for forthcoming
studies to address these issues in order to develop better
understanding of the anti-inflammatory properties of IL-4
during inflammation in mucositis.
5.2. Interleukin-10 (IL-10). IL-10 is the central anti-
inflammatory cytokine well researched in the pathogenesis
of Inflammatory Bowel Disease (IBD). Active IL-10 is
secreted by CD4+ Th2 cell, Treg, monocyte, and macrophage
cells of the immune system [56, 57]. Figure 2 shows the
IL-10 receptor activation that induces a wide range of
inflammatory controlling genes during tissue injury.
IL-10 controls inflammatory processes by suppressing
the expression of proinflammatory cytokines, chemokines,
adhesion molecules, as well as antigen-presenting and
costimulatory molecules in monocytes/macrophages, neu-
trophils, and T cells [57, 58]. Early in vitro studies demon-
strated IL-10 suppresses monocytes/macrophage-derived
proinflammatory cytokines such as TNF-α, IL-1, IL-6, IL-
8, and IL-12 [59, 60]. Additional studies support the notion
that IL-10 attenuates TNF-receptor expression and further
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Figure 2: Diagram illustrating the JAK-STAT signal transduction pathway activated by anti-inflammatory cytokine, Interleukin-10. IL-10
binds its high-aﬃnity extracellular IL-10 receptors in a homodimeric form which leads to intracellular receptor-associated Janus tyrosine
kinases, JAK-1 and TYK-2. These activated kinases serve a temporary docking-sites for the cytosolic STAT-3 via their phosphorylated SH-2
domain. Activated STAT-3 translocates to the nucleus and binds to STAT Binding Element (SBE) to promote a wide range of IL-10 responsive
genes.
promotes its shedding into systemic circulation [61, 62].
Together these findings indicated IL-10 is an important
immunoregulatory factor that significantly contributes to
decreasing the intensity of inflammatory response by down-
regulating proinflammatory cytokine production at the site
of tissue damage.
In an attempt to report the eﬀect of IL-10 on NFκB, in
vitro analysis by Clarke and Colleagues (1998) showed that
IL-10 is capable of inhibiting the activation of LPS-induced
NFκB in macrophages and pre-B cells [61]. This study
supports the evidence that IL-10mediates anti-inflammatory
eﬀects by inhibiting the up-stream NFκB transcription fac-
tor, an essential secondary messenger required for inducing
proinflammatory cytokine gene expression.
In the pathogenesis of IBD, the potent immunosuppres-
sive eﬀects of IL-10 have been highlighted in several studies.
The IL-10 knockout mouse model has successfully portrayed
spontaneous development of chronic inflammatory enteritis,
a condition similar to IBD in humans, suggesting that
endogenous IL-10 is a central regulator of the mucosal
immune response [63, 64]. Further dysregulation of the ratio
of pro/anti-inflammatory cytokines, IL-1β/IL-1ra, has been
associated with IL-10 administration in mucosal biopsies of
UC patients [65]. In addition, in vitro analysis by Schreiber
et al. (1995) also demonstrated that IL-10 downregulates the
enhanced production of proinflammatory cytokines from
IBD mononuclear phagocytes [66]. Thus, low production
of IL-10 anti-inflammatory cytokine in the mucosa of
IBD patients has been regarded as an important factor in
the pathogenesis of IBD. Such data in the pathogenesis
of mucositis lacks and investigation is warranted. Essen-
tially recognised as an inflammatory condition, the highly
complex and interactive nature of mucositis pathobiology
strictly limits our approach towards targeting an appropriate
molecular pathway. This evidence strongly supports the
notion that IL-10 is in fact a crucial cytokine with anti-
inflammatory properties that remains to be investigated in
the setting of chemotherapy-induced mucositis.
5.3. Interleukin-11 (IL-11). IL-11 is a well-known pleiotropic
cytokine. Physiological levels of IL-11 expression is identified
in a wide range of normal adult murine tissues including
thymus, spleen, bone marrow, heart, lung, small and large
intestine, kidney, brain, testis, ovary, and uterus [67, 68].
IL-11 functions to control inflammation, ameliorate tissue
damage, andmaintain cytokine haemostasis during infection
by acting on various cell types including hematopoietic
precursor cells, macrophages, adipocytes, epithelial, and T
cells [69, 70]. IL-11 mediates its biological activities by
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binding to its low aﬃnity IL-11α receptor (IL-11Rα) and
subsequently complexing with the gp130 signal transduction
subunit commonly shared with IL-6 receptor [70–72].
There is much evidence highlighting the anti-inflamma-
tory properties of IL-11 in duration of an inflammatory
response. Trepicchio et al. (1996) used mouse peritoneal
macrophages and eﬀectively demonstrated that rhIL-11
reduced the production of a wide spectrum of proinflamma-
tory mediators such as TNF-α, IL-1β, IL-12, and NO [73].
Furthermore, administration of rhIL-11 in mice reduced
proinflammatory cytokine production during a systemic
inflammation [73]. In a follow-up study to elucidate the
molecular mechanisms of IL-11 activity, in vitro analysis
in LPS-stimulated peritoneal macrophages by Trepicchio et
al. (1997) illustrated that rhIL-11 blocked nuclear translo-
cation of NFκB transcription factor and showed increase
cytoplasmic levels of the NFκB inhibitory proteins, IκB-α
and IκB-β [74]. In addition, mRNA detection of the IL-
11Rα and gp130 complex in human and murine CD4+ and
CD8+ lymphocytes suggests that IL-11 enhances the direct
production of T-cell-derived anti-inflammatory cytokines
such as IL-4 and IL-10 [76]. Together, these findings clearly
establish the immunoregulatory pleiotropic properties of
IL-11 in substantiating inflammatory responses during
cytokine-derived tissue injury.
Due to its potent anti-inflammatory nature, IL-11
has been under thorough investigation in several animal
models exhibiting inflammatory conditions such as gut
microorganism-induced sepsis [77], chronic IBD [78], and
ischemic bowel necrosis [79]. As a multifunctional cytokine,
IL-11 acts to attenuate the production of proinflammatory
cytokine in correlation with this ability to reduce inflam-
mation [75]. Flow cytometric analysis by Trepicchio and
Colleagues revealed that administration of rhIL-11 in vitro
successfully attenuated the production of IL-1β and TNF-
α from activated peritoneal macrophages [73]. Further-
more, rhIL-11 treatment also reduced serum levels of LPS-
induced IFN-γ, a well-known proinflammatory cytokine
that enhances inflammation through further activation of
macrophages [73, 80].
In the context of gastrointestinal inflammation, IL-11
has been of particular interest due to its anti-inflammatory
and mucosal protective eﬀects. In a rat model of colitis,
Peterson et al. (1998) demonstrated that rhIL-11 treatment
ameliorated the development of colitis by downregulat-
ing the production of proinflammatory cytokines as well
as maintaining the trophic structure of the gastrointesti-
nal epithelium [81]. Recombinant human IL-11 enhances
recovery from mucosal injury after cancer chemotherapy
treatment. Gibson and Colleagues investigated the eﬀect of
IL-11 on ameliorating mucositis in a rat model implanted
with syngeneic breast cancer following chemotherapy [49].
It was concluded that IL-11 has significant protective trophic
eﬀects on the intestinal epithelium as chemotherapy-related
damage of the villous atrophy and crypt length damage was
less severe. Also, IL-11 did not produce protective eﬀects on
the breast cancer tissue in this rat model of mucositis further
highlighting its eﬃcacy and safety upon administrating an
eﬀective dose [49]. In 1995, Sonis and Colleagues primarily
established that IL-11 decreases the severity and duration of
mucosal inflammation by protecting the intestinal epithe-
lium and connective tissue using a hamster model of oral
mucositis [82]. Liu et al. (1996) also demonstrated that
IL-11 significantly increased villus height and the rate of
crypt cell mitosis in the rat model of short bowel syndrome
[83]. The IL-11 receptor-α (IL-11Rα) is expressed within
the gastrointestinal epithelium and colonic epithelial cells
of the mucosa. In vitro studies have confirmed that IL-11
directly interacts on untransformed IEC-18 epithelial cells
to inhibit cellular proliferation [84, 85]. Although IL-11
is well researched in a number of diﬀerent inflammatory
conditions, current literature lacks to understand the direct
mechanism of IL-11 on the intestinal epithelium relating to
ameliorating chemotherapy-induced mucositis.
5.4. Interleukin-1 Receptor Antagonist (IL-1ra). IL-1 receptor
antagonist is a naturally synthesised and secreted 23–25-
kDa glycosylated protein produced primarily by monocytes,
macrophages, neutrophils, microglial cells, hepatocytes, and
many other cells in response to tissue injury, infection, and
inflammation [86, 87].
Extensive molecular research has established the central
biological role of IL-1ra as a highly competitive antagonist of
its functional proinflammatory ligands, IL-1α and IL-1β. For
many years, these isoforms of the IL-1 cytokine family have
been recognised to participate in initiating and amplifying
inflammation upon induced tissue injury and infection.
Amongst its various pleiotropic localised and systemic
eﬀects, IL-1 cytokines are known to promote inflammatory
cell infiltration at site of tissue injury, induce fever and
vascular dilation, promote NO, COX-2, and prostaglandin
E2 production, and induce production of other cytokine
mediators such as IL-6 [88].
Evidence from previous independent studies have iden-
tified that IL-1 cytokines, in particular IL-1β, play crucial
roles in the pathogenesis of various gastrointestinal tract
associated inflammatory conditions such as IBD, ischemic-
reperfusion injury, chronic enteritis, and irritable bowel
syndrome (IBS) [89].
An in vitro study by Al-Sadi and Ma (2007) has addi-
tionally highlighted the role of IL-1β on gastrointestinal
tract epithelial obliteration by successfully showing that
at a dose of 10 ng/mL, IL-1β eﬀectively increased tight-
cell junction permeability in the Caco-2 cell line 48 hours
following treatment [89]. This data provides strong evidence
that elevated IL-1β levels during intestinal injury further
amplifies inflammation by disrupting epithelial barrier and
increasing paracellular permeation of toxic luminal agents
into the mucosa [89].
Furthermore, Andus et al. (1997) proposed a lower IL-
1ra to IL-1 ratio in inflamed mucosa samples from patients
with Crohn’s Disease (CD) highlighting the importance of
localised tissue IL-1ra presence to downregulate excessive
inflammation [90]. IL-1ra animal models have also been
utilised in previous investigations to establish a clear under-
standing of the role of IL-1ra during inflammation. IL-1ra
gene knockout mice are known to be highly susceptible to
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suﬀering from endotoxemia and develop spontaneous joint
inflammation, arthritis thus resulting growth deficit [91].
In recent years, scientific research has shifted focus
towards determining the anti-inflammatory role of IL-1ra
during mucositis development. Preliminary microarray data
provided by Wu et al. (2011) identified the IL-1ra gene
to be highly expressed in correlation with increased serum
levels of IL-1ra after 5-FU treatment [92]. In a tumour-
bearingmousemodel of 5-FU-inducedmucositis, exogenous
application of IL-1ra significantly reduced intestinal crypt
cell apoptosis and severity of diarrhoea without aﬀecting 5-
FU-induced tumour regression [93]. Further comprehensive
analysis of the role of IL-1ra is necessary to validate
its protective anti-inflammatory eﬀects in the context of
chemotherapy-induced mucositis prior to its application in
a clinical setting.
6. Tregs and Cancer
Regulatory T cells, more commonly referred to as Tregs, are
responsible for the induction and maintenance of peripheral
tolerance, a critically important function enabling the body
to suppress immune responses by influencing diﬀerent
cell type activity [94]. Tregs make up approximately 10%
of thymus-derived CD4+ T cells, coexpressing the CD25
antigen (IL-2R α-chain), and requiring Fox3p transcription
factor expression for suppressive phenotype [95]. Two main
types of Tregs exist, natural and peripherally-induced, with
natural Tregs primarily responsible for controlling immune
responses to autoantigens [94], and induced Tregs inhibiting
inflammation [94, 96]. Both types of Tregs contribute to
overall tumour tolerance in many cancers including, but not
limited to pancreatic, [97] ovarian [98], melanoma [99], and
renal cell carcinoma [96, 100]. Given the importance of Tregs
in tumour tolerance, Tregs, have gained increased recogni-
tion in cancer patients and treatments. Wolf and Colleagues
(2003) examined the Treg levels in peripheral blood samples
of 42 cancer patients and 34 healthy controls and found
cancer patients had increased numbers of Tregs compared
with controls. Importantly, these increases were associated
with immunosuppression. The authors suggested that the
increase in Tregs in cancer patients may negatively impact
the eﬀectiveness of immunotherapies including monoclonal
antibody therapy [101].
Most relevant to this paper, one of the immune sup-
pressive mechanisms by which Tregs maintain immune
homeostasis is through secretion of the anti-inflammatory
cytokines IL-10 and TGFβ [102]. Importantly, IL10 is
required to maintain immune homeostasis in the gut, where
Treg-specific deletion of IL-10 leads to colitis in mice
[103]. Since evidence shows that Th1 immune responses
simultaneously stimulate Treg induction [102], prevention
of inflammation should theoretically be an eﬀective means
of limiting Treg-produced anti-inflammatory cytokines.
6.1. Therapy Options for Tregs. A number of clinical studies
have been reported in recent years examining the potential
use of Tregs as a specific marker of treatment response in a
number of diﬀerent cancer types. Kaufman and Colleagues
conducted a small clinical study to examine the eﬀectiveness
of interleukin-2 on Treg responses inmetastatic renal cell car-
cinoma. They enrolled 25 patients and found that although
Tregs were elevated in all patients prior to treatment, in
patients who achieved stable disease state a 50% reduction in
the Tregs was seen. These findings suggest that interleukin-2
therapy is eﬀective in reducing Tregs, although the study was
extremely small [100]. These findings are in agreement with
an earlier clinical study, whereby 11 patients with renal cell
carcinoma vaccinated with DAB389IL-2 (recombinant IL-2
diphtheria toxin) had their Tregs eliminated from peripheral
cells [95].
Ascierto et al. [99] evaluated the Treg levels in 22
melanoma patients following IFN-a 2b therapy and reported
that prior to therapy, Treg levels were significantly higher
(P < 0.001) in melanoma patients compared to healthy
controls. Following therapy, Treg levels decreased although
this did not reach significance. The authors suggested that it
was impossible to draw any conclusions regarding Tregs as a
marker to cancer treatment response due to small sample size
[99].
There are many other papers which suggest a variety of
ways in which Tregs can be “managed” in the context of
cancer. These include histone deacetylase inhibitors (which
would augment the suppressive function of Tregs) [104],
retinoids [105], Dendritic cell vaccines [106], and blocking
either Treg eﬀector functions [107] or Treg diﬀerentiation
[108]. This list is by nomeans exhaustive, but a more detailed
analysis is beyond the scope of this paper.
7. Conclusions
In the past decade, active research has been conducted to
define the pathogenesis of mucositis and the role of proin-
flammatory cytokines TNF-α, IL-6, and IL-1β. Evidence of
the upregulation of these proinflammatory cytokines coordi-
nated with the extent of mucosal injury in mucositis proves
to be valuable. This subclass of cytokines is recognised to play
an enormous role during inflammation and tissue damage
in response to cytotoxic therapy. There remains, however,
a huge gap in the knowledge to recognise whether anti-
inflammatory cytokines such as IL-4, IL-10, IL-11, and IL-
1ra are essential tools in downregulating the inflammatory
response associated with mucositis. Lack of this knowledge
which ties pro- and anti-inflammatory cytokines together
within the complex yet interesting cytokine milieu leaves
an incomplete image of immune response associated with
mucositis. Furthermore, there is no evidence in literature
that interprets the net balance of the subclass of cytokines
in accordance with diﬀerent phases of mucositis devel-
opment. Moreover, the underlying mechanisms of action
of these anti-inflammatory cytokines in chemotherapy-
induced mucositis remain underresearched. Taking into
consideration the lack of knowledge of anti-inflammatory
cytokines in the setting of chemotherapy-induced mucositis,
it is obligatory for future cytokine studies of inflammation
to base their research on identifying and interpreting the
8 Chemotherapy Research and Practice
interrelationships of anti-inflammatory cytokines in the
pathogenesis of mucositis.
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